Novavax, Inc. (NASDAQ: NVAX) is tumbling in the market this morning with no real news that has been released as the catalyst. After scouring message boards, we found several investors saying that this was a discount in the making, but is it? What’s coming up that makes them believe that? Today, we’ll talk about:
- Whether or not we believe that NVAX is a discount in the making;
- what we’re seeing from the stock; and
- what we’ll be watching for ahead.
Is NVAX Presenting A Discount
As mentioned above, Novavax is falling in the market this morning, leading many to mention that this is a discount in the making. So, what’s the deal?
Well, late last year, we were looking for two big pieces of news to come from the company The first of which was data out of a Phase 2 study of NanoFlu in older adults. The NanoFlu data was released and proved to be positive.
The trial hit its primary endpoint, demonstrating an improved immune reponse when vaccinated with the product. This led the company to say that it would be holding a meeting with the FDA in the first half of the year and plans on initiating a Phase 3 trial for the asset by the end of the year.
So, we have a few catalysts there. However, after digging a bit, it became clear that these aren’t the only catalysts that investors may be eluding to when mentioning a discount.
Another product in the making at NVAX is a RSV-F vaccine, known as ResVax. The treatment is currently in Phase 3 trials and data is expected to come some time in the first quarter. Considering that we have passed the half-way point in the quarter, the catalyst is likely on the horizon.
Considering the recent news out of NVAX as well as coming catalysts, the declines in the price of the stock today could prove to be a discount. While there are always risks to consider, investors in the message boards may be onto something here.
What We’re Seeing From The Stock
While there has been no real news released by Novavax, the stock is having a hard day in the market today. As is normally the case, our partners at Trade Ideas were the first to alert us to the declines. Currently (10:40), NVAX is trading at $1.90 per share after a loss of $0.095 per share or 4.75% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the story surrounding the company’s continued development of both NanoFlu and ResVax as there are several catalysts surrounding these products ahead. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!